V Rao1, J R Spiro, P B Rosenberg, H B Lee, A Rosenblatt, C G Lyketsos. 1. Division of Geriatric Psychiatry and Neuropsychiatry, Department of Psychiatry & Behavioral Sciences, The Johns Hopkins School of Medicine, Baltimore, MD, USA. vrao@jhmi.edu
Abstract
BACKGROUND: Depression is a frequent neuropsychiatric complication of Alzheimer's Disease. METHODS: This study investigated the safety and effectiveness of escitalopram (LEXAPRO) for depression in AD (dAD) as defined by the NIMH consensus criteria in an 8-week, open-label treatment study. CONCLUSION: Escitalopram was efficacious and safe for the treatment of dAD in this study. Larger, controlled studies are warranted to further assess the efficacy for mood and behavioral disturbances in this medically fragile population.
BACKGROUND:Depression is a frequent neuropsychiatric complication of Alzheimer's Disease. METHODS: This study investigated the safety and effectiveness of escitalopram (LEXAPRO) for depression in AD (dAD) as defined by the NIMH consensus criteria in an 8-week, open-label treatment study. CONCLUSION:Escitalopram was efficacious and safe for the treatment of dAD in this study. Larger, controlled studies are warranted to further assess the efficacy for mood and behavioral disturbances in this medically fragile population.
Authors: Martin Steinberg; Kyle Hess; Chris Corcoran; Michelle M Mielke; Maria Norton; John Breitner; Robert Green; Jeannie Leoutsakos; Kathleen Welsh-Bohmer; Constantine Lyketsos; Joann Tschanz Journal: Int J Geriatr Psychiatry Date: 2013-05-17 Impact factor: 3.485